News
Michael Dewey Loberg, 78, a scientist, pharmaceutical entrepreneur, sailor, local health advocate, and enemy of tick-borne ...
23hon MSN
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
Three quality stocks that generate a lot of dividend income you may want to consider are Verizon Communications (NYSE: VZ), ...
Stockhead on MSN16h
Morgans spotlights nine healthcare stocks with upcoming catalysts after “upbeat” Bioshares Biotech Summit
Morgan's Scott Power highlights nine ASX healthcare companies from the 2025 Bioshares Biotech Summit with catalysts over next six ... Read More The post Morgans spotlights nine healthcare stocks with ...
DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...
Zacks.com on MSN21h
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis(EXEL) is developing zanzalintinib— a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback